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Summary
Background: Our earlier studies on Human Leucocyte Antigens (HLA) in pulmonary tuberculosis patients revealed the
association of HLA-DR2 antigen with susceptibility to pulmonary TB and DR2 antigen has been shown to influence the
immunity to tuberculosis.
Objectives: The present study  was carried out to find out whether HLA-DR antigens are associated with susceptibility
to spinal tuberculosis.  Moreover, the role of HLA-DR antigens on lymphoproliferative response to Mycobacterium
tuberculosis culture filtrate antigens was studied using Lymphocyte Transformation Test (LTT).
Material and Methods: HLA-DR genotyping and lymphoproliferative response was carried out in 63 cured spinal TB
patients and 63 control subjects (spouses of pulmonary and spinal TB patients).
Results: A trend towards an increased frequency of HLA-DR9 antigen was observed in spinal TB patients compared  to
controls. A significantly decreased lymphocyte response to M. tuberculosis antigens was observed in HLA-DR9 antigen
positive control subjects compared to HLA- DR9 antigen negative subjects (P=0.0009) whereas increased response was
observed with DR9 positive cured spinal TB patients compared to HLA-DR9 antigen negative patients. Further, HLA-
DR3 antigen positive patients showed a decreased lymphocyte response compared to HLA-DR3 antigen negative
patients (P<0.05).
Conclusion: The study suggests that HLA-DR9 antigen either alone or in combination with other HLA antigen as
lhplotype and non-HLA genes may be associated with susceptibility to spinal TB and play a regulatory role on the
immune response to M. tuberculosis in spinal tuberculosis patients.
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INTRODUCTION
Spinal tuberculosis, a degenerative disease
of the spine caused by Mycobacterium tuberculosis,
also known as Pott’s disease, usually occurs due to
lymphohaematogenous spread from a primary focal
area, such as the lung. It may also result from direct
invasion of a paravertebral focus by lymphangitic
spread from paravertebral lymph nodes or the pleural
space1,2. Our earlier studies in pulmonary tuberculosis
revealed the association of HLA-DR2 antigen with
the susceptibility to pulmonary tuberculosis3.  Our
further studies also revealed the influence of HLA-
DR2 antigen on antibody titre, spontaneous
lymphoproliferative response and antigen induced
lymphocyte response including memory response in
pulmonary tuberculosis4,5.
Earlier, we have studied the humoral and
lymphocyte response to M. tuberculosis antigens in
cured spinal tuberculosis patients and the immune
response pattern was compared with the contacts6.
The present study was carried out to find out whether
HLA-DR2 antigen is associated with the susceptibility
to spinal tuberculosis. Moreover, the influence of
HLA-DR genes on lymphoproliferative response to
M. tuberculosis antigens was studied to understand
the memory response, if any, in cured spinal TB
patients.
MATERIAL  AND METHODS
Spinal tuberculosis patients:  Patients
included in this study were cured spinal tuberculosis
patients who were treated 15-20 years ago. A total
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of 63 patients were studied, of which 39 were
females (mean age ± standard error (SE) = 45.7±2.2
yrs) (range 21-78 yrs) and 24 were males (mean
age±SE = 40.0±3.3 yrs) (range 21 -74 yrs). These
patients were selected from subjects of an earlier
chemotherapy study carried out at our centre7.
Clinically and radiographically active spinal
tuberculosis patients involving any vertebral body
from the first thoracic to the first sacral  were
admitted to the chemotherapy study.  Patients were
excluded if they had (a) paralysis of the lower limb
severe enough to prevent them from walking (b)
serious extraspinal disease, tuberculous or non-
tuberculous (c) history of previous chemotherapy
for 12 months or more, or (d) already had major
surgery for their spinal tuberculosis. All the patients
were in quiescent stage at the time of blood sample
collection for the present study.
Controls:  Normal healthy spouses of the
spinal tuberculosis patients and pulmonary
tuberculosis patients were studied. Of the 63 contacts
studied, 39 were females (mean age ± SE = 36.5 ±
1.5 yrs) (range 20-60 yrs) and 24 were males (mean
age ± SE = 43.4 ± 2.7 yrs) (range 23 -65 yrs). The
contacts were clinically normal at the time of blood
sample collection. The spouses were living together
with the patients before, during and after treatment
for about 15-20 years. The patients and the controls
belonged to the same ethnic origin, socio-economic
status and were not consanguineous.
Lymphoproliferative response to Mycobacterium
tuberculosis antigen:  Peripheral blood mononuclear
cells (PBMC) were separated from heparinised (20
units/ml) blood samples using Ficoll-Hypaque density
gradient centrifugation8.  Lymphocyte transformation
test (LTT) to culture filtrate antigen of M. tuberculosis
(10 µg/ml) was carried out as described in our earlier
study4.
Extraction of human genomic DNA:  DNA was
extracted from peripheral blood white cells using a
salting out procedure9.
Genotyping of HLA-DR:  DNA typing of HLA-DR
was done using a combination of Group Specific
Amplifications (GSA), Amplified Fragment Length
Polymorphism (AFLP) and hybridization with
Sequence Specific Oligonucleotide Probes (SSOP),
which involved two sequential steps: first, GSA for
six groups of HLA-DR generic types with group
specific primers: DR1, DR2, DR4, DR10, DR7 and
DR9 and finally DR3, DR5, DR6, DR8. At the end
of the first step DR1, DR2, DR4 and DR10 were
assigned directly based on the presence or absence
of amplified polymerase chain reaction (PCR)
product, DR7 and DR9 were assigned by AFLP after
digestion of amplified DNA with the endonuclease
HinfI10.  Second, DNA typing of DR3, DR5, DR6
and DR8 in the second exon of the DRB gene was
done by group specific amplification using a set of
primers and then by using SSOP to assign the generic
types11.
Statistical Methods:  The frequencies of HLA-DR
antigens in patients and contacts were determined
by direct allelic count and expressed as percent
phenotype (% PF).  2x2 Chi-square test (χ2) was
performed for ascertaining the significance of the
HLA antigens.  The P value (with Yates’ correction)
was determined to find out the significance. Relative
risk  (RR) was calculated using the appropriate
formula12.  The results on the lymphoproliferative
response was analysed using Student’s t test and
the significance was determined. Results of the
lymphoproliferative response are expressed as
arithmetic mean ± standard error (S.E.). P value less
than 0.05 was considered significant.
RESULTS
Among the various HLA-DR antigens,
increased antigen frequency and relative risk were
observed with HLA-DR9 in spinal TB patients as
compared to control subjects (DR9: Spinal TB 12.7%;
Control 3.2%) (Relative Risk DR9: 1.7). The antigen
frequency of HLA-DR2 was similar to that of
controls [spinal TB : 31.7%; control: 30.2%] (Table).
The lymphoproliferative response to M.
tuberculosis antigen of cured spinal TB patients was
similar to control subjects. The Stimulation Index
(SI), of controls was 9.0 ± 1.4, whereas the SI was
9.7 ± 1.6 in cured spinal TB patients.  Moreover, no
difference was observed irrespective of the DR
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phenotype of the patients and control subjects. HLA-
DR9 positive control subjects showed a significantly
low lymphocyte response to M. tuberculosis culture
filtrate antigens (Control : DR9 positive vs DR9
negative : P=0.0009).  An increased lymphocyte
response was observed in -DR9 positive cured spinal
TB patients than -DR9 negative patients. Spinal TB
patients positive for HLA- DR3 and HLA-DR10
antigens showed a decreased lymphocyte response
to M. tuberculosis antigens (DR3 positive vs DR3
negative : P<0.05; DR10 positive vs DR10
negative : P=0.002) when compared to HLA-DR3
and HLA-DR10 negative patients (Figure).
DISCUSSION
In the present study, a trend towards an
increased antigen frequency of HLA-DR9 (12.7%)
was observed with the spinal TB patients compared
to control subjects (DR9 : 3.2%) (DR-9 Relative
Risk : 1.7).  Further, in the present study, HLA-DR2
Figure: Influence of  HLA-DR antigens on lymphocyte response to M. tuberculosis culture  filtrate
antigens (10 µg/ml) in cured spinal TB patients and controls.  Results are expressed as arithmetic
mean  ± S.E of the stimulation index. Numbers in parentheses represent the subjects studied.
£P=0.0009;*P<0.05;$P=0.002
Table: Percentage  phenotype  frequencies  of
HLA-DR antigens in spinal TB patients
and controls
n = Number of individuals studied; numbers in parentheses represent
the individuals positive for each antigen.  * HLA-DR9 χ2 uncorrected
p=0.048 (significant).  Relative Risk: DR9:1.7
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HLA  ANTIGENS % Phenotype frequency 
 Controls 
(n=63) 
Spinal TB 
(n=63) 
HLA-DR   
DR 1 12.7 (8) 19 (12) 
DR 2 30.2 (19) 31.7 (20) 
DR 3 20. 6 (13) 14.3 (9) 
DR 4 28.6 (18) 20.6 (13) 
DR 5 25.4 (16) 22.2 (14) 
DR 6 33.3 (21) 30.2 (19) 
DR 7 28.6 (18) 31.7 (20) 
DR 8 9.5 (6) 4.8 (3) 
DR 9 3.2 (2)  12.7 (8) 
DR 10 7.9 (5) 12.7 (8)  
DR blank 0 0 
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(control : 30.2%; Spinal tuberculosis : 31.7%) was
not found to be associated with the susceptibility to
spinal TB, whereas our earlier study showed the
association of HLA-DR2 (Control: 29.5%;
pulmonary TB : 48.8%) with the susceptibility to
pulmonary TB. In south Indian patients with
pulmonary TB, DR2 has been shown to be more
strongly associated with far advanced, smear positive
cases than with cases with minimal and moderate
radiographic lung lesions13.  On the other hand, spinal
tuberculosis is a localized disease with paucibacillary
state.  Our recent study on vitamin D receptor gene
(non-HLA gene) polymorphism (BsmI, ApaI, TaqI
& FokI polymorphism), revealed the association of
the genotypes Bb (heterozygotes) of BsmI
polymorphism and FF (homozygotes of frequent
allele ‘F’) of FokI polymorphism of vitamin D
receptor gene with the susceptibility to spinal
tuberculosis14.  Probably HLA-DR9, either alone
or in combination with other HLA antigen as
haplotype and non-HLA genes, may be associated
with paucibacillary disease such as spinal
tuberculosis.
The lymphoproliferative response to M.
tuberculosis culture filtrate antigens of cured
spinal TB patients did not differ from control
subjects. This suggests that normal immune
response is restored in cured spinal TB patients
and is similar to that of normal subjects. HLA-
DR9 antigen positive control subjects showed a
decreased proliferative response to M. tuberculosis
antigens compared to - DR9 antigen negative control
subjects. An increased response with -DR9 positive
patients was observed as compared to -DR9 negative
patients. This suggests that HLA-DR9 antigen may
be associated with low responder status to M.
tuberculosis infection which may probably allow the
pathogen to establish the infection in a susceptible
DR9 positive normal subjects and associated with
increased lymphoproliferative response during
disease state.
In the present study, cured spinal TB
patients positive for HLA-DR3 and -DR10 antigens
showed a significantly decreased lymphocyte
response to M. tuberculosis antigens. HLA- DR3
associated non-responder status of T-lymphocyte
responses to PPD has been reported15.  The
decreased response associated with DR3 has been
suggested to be due to decreased IL-2 production16.
A similar mechanism may also be possible for the
lower lymphocyte response observed in DR3 and
DR-10 positive cured patients.
The present study suggests that HLA-DR9
either alone or in combination with other HLA
antigens as haplotype and non-HLA genes such as
vitamin D receptor gene may be associated with
susceptibility to spinal tuberculosis. Further, HLA-
DR9 may also play a regulatory role on the immunity
to M. tuberculosis in spinal tuberculosis.
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What To Do For Quitting
Smoking
After making a firm resolve to quit smoking, you may take the
following steps :
1. Consult your doctor. He is bet placed to show you the way and
help you medically at cruical junctures.
2. Join or form a group/an association of smokers who have
successfully quitted, like the Alcoholics Anonymous for drinkers.
3. Read guide-book about quitting smoking.
4. Keep trying instead of thinking how difficult it is to quit or the
pleasure you might get from just a single cigarette.
5. Talk freely to other smokers about how you are already succeding.
And advise the vulnerable non-smokers why they should never
start the habit. This activity will help boost your own morale.
6. Finally, have full faith in your own self. You are the one who is
going to succeed. Do not deprive yourself of some therapies that
are available for ‘nicotine replacement’, if your doctor so advises.
YOU HAVE TO QUIT
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